NEW YORK, July 1 (GenomeWeb News) - Ciphergen Biosystems expects a significant drop in revenues for the second quarter and plans to cut costs in its instrumentation division, the company said yesterday.

 

Ciphergen estimates revenues of $10-11 million for the quarter ending yesterday, down from $14.3 million during the same period last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.